Silence Therapeutics (SLN) Net Equity Issued and Repurchased (2024 - 2025)

Silence Therapeutics (SLN) reported Net Equity Issued and Repurchased of $1000.0 for Q2 2025, down 99.92% on a YoY basis from $1.2 million in Q2 2024, and down 92.86% sequentially from $14000.0 in Q1 2025.

Silence Therapeutics (SLN) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends

Silence Therapeutics (SLN) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $1000.0 in Q2 2025.

  • For the quarter ending Q2 2025, Net Equity Issued and Repurchased fell 99.92% year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at $1000.0 (down 99.99% YoY), and the FY2025 full-year result was $15000.0, down 99.99% from the prior year.
  • Net Equity Issued and Repurchased slipped to $1000.0 in Q2 2025, from $14000.0 in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $133.0 million in Q1 2024 to a low of -$98000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Silence Therapeutics 1.62 Bn 1.49 Bn 411,000.00 -

Historic Data

Download Data
DateValue
Jun 30, 2025 1,000.00
Jun 30, 2025 1,000.00
Mar 31, 2025 14,000.00
Mar 31, 2025 14,000.00
Dec 31, 2024 -98,000.00
Dec 31, 2024 -98,000.00
Sep 30, 2024 7.97 Mn
Sep 30, 2024 7.97 Mn
Jun 30, 2024 1.19 Mn
Jun 30, 2024 1.19 Mn
Mar 31, 2024 133.02 Mn
Mar 31, 2024 133.02 Mn